Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered paper session 2

2040 - Biomarker analysis of randomized controlled trial (RCT) of adjuvant chemotherapy (CT) using plasma EBV DNA to identify patients (pts) at higher risk of relapse after radiotherapy (RT) or chemoradiation (CRT) in nasopharyngeal cancer (NPC) (336O)

Date

18 Nov 2017

Session

Proffered paper session 2

Presenters

Edwin Hui

Citation

Annals of Oncology (2017) 28 (suppl_10): x100-x110. 10.1093/annonc/mdx665

Authors

E.P. Hui1, A.T.C. Chan1, R.K.C. Ngan2, S.Y. Tung3, A.C.K. Cheng4, W.T. Ng5, V.H. Lee6, B. Ma1, H.C. Cheng2, F.C.S. Wong3, H.H. Loong1, M. Tong1, D.M. Poon1, A.T. Ahuja7, A.D. King7, K. Wang7, F. Mo1, B.C. Zee8, K.C.A. Chan9, Y.M.D. Lo9

Author affiliations

  • 1 Department Of Clinical Oncology, The Chinese University of Hong Kong, - - Shatin/HK
  • 2 Department Of Clinical Oncology, Queen Elizabeth Hospital, 000000 - Hong Kong/HK
  • 3 Department Of Clinical Oncology, Tuen Mun Hospital, 000000 - Hong Kong/HK
  • 4 Department Of Clinical Oncology, Princess Margaret Hospital, 000000 - Hong Kong/HK
  • 5 Department Of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, 000000 - Hong Kong/HK
  • 6 Department Of Clinical Oncology, Queen Mary Hospital, 000000 - Hong Kong/HK
  • 7 Department Of Radiology, The Chinese University of Hong Kong, - - Shatin/HK
  • 8 Center For Clinical Trials, School Of Public Health, The Chinese University of Hong Kong, - - Shatin/HK
  • 9 Department Of Chemical Pathology, The Chinese University of Hong Kong, - - Shatin/HK
More

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 2040

Background

The benefit of adjuvant CT in NPC is controversial. We conducted a biomarker guided RCT using post-RT EBV DNA to select high risk NPC pts for adjuvant CT while sparing low risk pts from unnecessary toxicity.

Methods

Eligible NPC pts of AJCC (6th Ed) stage IIB-IVB, ECOG 0-1, adequate organ functions, no locoregional disease or distant metastasis after RT/CRT, were screened for plasma EBV DNA at 6-8 weeks post-RT. Pts with EBV DNA =0 (copies/ml) were observed. Pts with EBV DNA >0 underwent work-up and were randomized to arm A (adjuvant cisplatin-gemcitabine x 6 cycles) or arm B (observation). Primary endpoint for the RCT was relapse free survival (RFS). With a hazard ratio (HR) of 2, 100 randomized pts were required for a power of 0.8 and an alpha at 0.05.

Results

From 9/2006 to 7/2015, 789 pts were screened by plasma EBV DNA: 573 (72.6%) pts had EBV DNA =0, 216 (27.4%) pts had EBV DNA >0, 104 (13.2%) pts were randomized (arm A: 52; arm B: 52). The clinical characteristics and significant biomarkers (post-RT EBV DNA levels: 1-49/50-499/>=500; PET-CT scan: negative/positive) were evenly balanced in the two arms. After median follow up of 6.6 years (yr), there was no significant difference in RFS or overall survival (OS) between the two arms in the intent-to-treat and per protocol population, and by subgroup analysis defined by EBV DNA level and PET-CT. By recursive partitioning analysis (RPA), we identified three prognostic groups among 789 post-RT NPC pts (Table). The low risk group (EBV DNA < 50 and stage II/III) shared the same survival (5-ys OS 89%) as stage II but included more than twice the number of pts.Table: 336O

Risk groupsN (% of total population, n = 789)No. of events3-yr OS rate (95% C.I.)5-ys OS rate (95% C.I.)HR (95% C.I.)P value
TNM stages
(1) Stage II220 (27.9%)3692.5 (88.1-95.4)88.2 (82.9-92.0)1.00
(2) Stage III374 (47.4%)7288.3 (84.4-91.2)81.2 (76.3-85.2)1.45 (0.97-2.17)P = 0.069
(3) Stage IV195 (24.7%)7379.1 (72.5-84.3)67.3 (59.5-73.9)3.08 (2.06-4.59)P 0216 (27.4%)8970.8 (64.1-76.5)60.2 (52.9-66.8)3.18 (2.38-4.27)P 

Conclusions

Adjuvant CT with cisplatin-gemcitabine did not improve survival in high risk NPC pts with detectable post-RT plasma EBV DNA. The low risk group (includes 66% of pts) can potentially be spared the toxicity of adjuvant CT.

Clinical trial identification

NCT00370890

Legal entity responsible for the study

Comprehensive Cancer Trials Unit, Department of Clinical Oncology, The Chinese University of Hong Kong

Funding

Support by central research funds from Hong Kong Hospital Authority and The Chinese University of Hong Kong. Gemcitabine provided by Eli Lilly.

Disclosure

E.P. Hui: Advisory Board: MSD, BMS; Speaker Honorarium: MSD. A.T.C. Chan: Research funding: Pfizer, Boehringer Ingelheim, BMS, MSD Travel, accomodation and expenses: Roche, Pfizer, Novartis, BMS. R.K.C. Ngan: Travel, accomodation and expenses: Eisai, Merck, Pfizer, Roche, Novartis. V.H. Lee: Honorarium: Roche, Eli Lilly, Pfizer. B.C. Zee: Patent, royalties: Health View Bioanalytics. K.C.A. Chan: Patents, royalties, other intellectual property: Sequenom, Illumina, Xcelom, Cirina. Stock or other ownership: Cirina, Xcelom. Honoraria, travel, accomodations, expenses: Biorad. Consulting or advisory role: Xcelom.

All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.